**HEMATOLOJİ BİLİM DALI TEDAVİ ve TAKİP FORMU**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ad-SOYAD: DİYAP FAYAD | | | | | | | | TANI: **Hairy cell lösemi** | | | | | | | | |
| Yaş / Cins: 68/E | | | | | | | | Tedavi: | | | | | | | | |
| Tanı tarihi: | | | | | | | | Tedaviye başlama tarihi: | | | | | | | | |
| Vücut yüzeyi: 2 m2  (boy: 165 cm, ağırlık: 93 kg) | | | | | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | | | |
| **Tarih** | **Tarih** | **2-klorodeoksiadenozin (2-CDA, Kladribin)**  **0.1mg/kg/gün**  **mg/gün** |  | | **Antibiyotikler** | | | | | | | **Transfüzyonlar** | | | | **ATEŞ** |
|  |  | |  | | | |  |  | **TDP** | **Eritrosit** | **Trombosit** | **Fibrinojen** |
| **1** |  | **+** |  |  | | |  | |  |  |  |  |  |  |  |  |
| **2** |  | **+** |  |  | | |  | |  |  |  |  |  |  |  |  |
| **3** |  | **+** |  |  | | |  | |  |  |  |  |  |  |  |  |
| **4** |  | **+** |  |  | | |  | |  |  |  |  |  |  |  |  |
| **5** |  | **+** |  |  | | |  | |  |  |  |  |  |  |  |  |
| **6** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **7** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **8** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **9** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **10** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **11** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **12** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **13** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **14** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **15** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **16** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **17** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **18** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **19** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **20** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **21** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **22** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **23** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **24** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **25** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **26** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **27** |  |  |  |  | | |  | |  |  |  |  |  |  |  |  |
| **28** |  |  |  | | | |  | |  |  |  |  |  |  |  |  |
| **\*2-klorodeoksiadenozin (**Kladribin)**: 13** mg/gün Kladribin subkutan uygulanacak | | | | | | | | | | | | | | | | |